Cargando…
In Reply
This letter to the editor responds to remarks on a recently published article about dermatologic events associated with enfortumab vedotin and agrees that education on the prevention and management of such events should be a priority.
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526498/ https://www.ncbi.nlm.nih.gov/pubmed/36036599 http://dx.doi.org/10.1093/oncolo/oyac171 |
| Sumario: | This letter to the editor responds to remarks on a recently published article about dermatologic events associated with enfortumab vedotin and agrees that education on the prevention and management of such events should be a priority. |
|---|